1 Broadway # 14, Cambridge, MA 02142
CDK 4/6 inhibitors are an important drug class in 1st line metastatic breast cancer. Unfortunately, resistance inevitably develops and causes treatment failure and the patient’s cancer progresses. Here we show that SDX-7320 overcomes many of the known mechanisms of developed resistance to CDK 4/6 inhibition. 2021 AACR Poster Apr 2021
Leptin may be a primary mediator of exercise-induced improvements in breast cancer recurrence.
The opportunity to draw upon genetic data from large-scale, international consortia allows for triangulation of evidence using distinct methodological approaches that make orthogonal underlying assumptions and suffer from distinct sources of bias. The findings of our study support a potential causal effect of genetically predicted T2DM and/or fasting insulin levels, rather than genetically predicted fasting […]
“We would expect at some point cancer would overtake vascular disease as a leading cause of death, both in the general population and among people with diabetes,” Song told Healio. “What surprises me most is the magnitude of the gap. If you look at the number for total cancer deaths, it is almost twice as […]
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
SynDevRx, Inc., a clinical-stage biopharmaceutical company specializing in metabo-oncology, has announced the formation of its Prostate Cancer Medical Advisory Board (PCMAB), comprised of key opinion leaders and industry experts in clinical oncology research and prostate cancer patient care. The board’s overarching goal is to inform the development of SynDevRx’s lead drug candidate, SDX-7320, to target […]
With a global epidemic of obesity and diabetes and their known relationship to cancer, researchers and oncologists are turning their attention to metabolic hormones as promising new targets for cancer treatment.
Patients that are not cured with surgery or radiation are largely treated with endocrine therapies that target androgens or the androgen receptor (AR), a major driver of PCa. In response to androgen deprivation, most PCas progress to castrate resistant PCa. Epidemiological studies suggest that high-fat diets play important roles in PCa progression. Lipid metabolism rewires […]
Technology Networks recently spoke with Jim Shanahan, co-founder, chief business officer and director of SynDevRx, to explore the impact of metabolic dysfunction on treatment outcomes and learn more about the company’s lead compound SDX-7320.
Obesity has been linked to increased risk for over a dozen different types of cancer, as well as worse prognosis and survival. Over the years, scientists have identified obesity-related processes that drive tumor growth, such as metabolic changes and chronic inflammation, but a detailed understanding of the interplay between obesity and cancer has remained elusive. […]